Moreover, future clinical trial designs should focus on assessing the safety, efficacy, and optimal dosing of IFN‐γ platelet treatments in human subjects, aiming to establish new therapeutic strategies for autoimmune diseases like Type 1 diabetes. This evidence concerns the gene IFNG and type 1 diabetes mellitus.